Telomir selects Linical for FDA-cleared phase 1/2 TNBC trial
Telomir Pharmaceuticals has executed agreements with CRO Linical to advance the clinical trial of Telomir-Zn in triple-negative breast cancer, targeting initiation in Q1 2027. The financial impact on Telomir is currently immaterial pending results.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed